Although they can be uncomfortable, recognising the factors that trigger them can help you take practical steps to reduce their impact
Results Treatment driven phenotype As depicted in Fig
There is no one-size-fits-all answer, which is exactly why I personalize every recommendation
However, this was supported by moderate-quality evidence and based on analyses of all patients with T2DM, rather than those with chronic coronary disease [43]
Additionally, several key clinical trial readouts delivered compelling data across multiple indications, for example (see Figure 1): Semaglutide : STEP-HFpEF (functional benefits in HFpEF), STEP-9 (pain reduction in knee osteoarthritis), STEP-10 (reversion to normoglycaemia in pre-diabetic, obese patients), ESSENCE (resolution of MASH, improvement in fibrosis) Tirzepatide : SUMMIT (risk reduction in HFpEF outcomes